Background: Selective serotonin reuptake inhibitors (SSRIs) are first-line treatments for major depressive disorder and anxiety disorders. Sexual dysfunction is among their most common adverse effects, impairing quality of life and treatment adherence. Increasing attention has focused on post-SSRI sexual dysfunction (PSSD), in which symptoms persist after antidepressant discontinuation. Objective: To summarize current evidence on sexual physiology, mechanisms and clinical features of antidepressant-induced sexual dysfunction (AISD) and PSSD, and available management strategies. Methods: A narrative review of English-language literature published between 2020 and 2026 was conducted using PubMed and Google Scholar. Original studies, systematic reviews, meta-analyses, randomized trials, observational studies, and relevant case reports were included, along with essential earlier landmark publications. Results: SSRI-associated sexual dysfunction may affect desire, arousal, erection, ejaculation, orgasm, and sexual satisfaction. Prevalence estimates vary because of differences in study populations and assessment methods. Symptoms usually improve after dose reduction or discontinuation, but may persist as PSSD. Proposed mechanisms include serotonergic dysregulation, altered dopaminergic and neuroendocrine signaling, epigenetic changes, TRP ion channel dysfunction, neurotoxicity, and gut–brain axis disturbances, although none has been confirmed. Management includes dose reduction, switching to antidepressants with a lower risk of sexual adverse effects, pharmacological augmentation, and selected non-pharmacological interventions. No evidence-based treatment for PSSD has been established. Conclusions: Sexual dysfunction is a major adverse effect of SSRI therapy. Routine assessment before and during treatment may facilitate recognition and management. High-quality prospective studies are needed to clarify the epidemiology, mechanisms, and optimal treatment of PSSD.